Drug Profile
Metformin controlled release - HanAll Biopharma
Alternative Names: Glucodown OR; Glucodown OR sustained-release tablets - HanAll; HL-018; HL001; HL002; Metformin 500mg + 750mg optimised release tablets - HanAll; Metformin OR tablets - HanAllLatest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator HanAll Biopharma
- Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diabetes mellitus
- Discontinued Obesity
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Obesity in South Korea (PO) (HanAll Biopharma pipeline, February 2023)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Obesity in South Korea (PO)
- 30 Oct 2018 HL 018 is still in preclinical trials for Obesity in South Korea (Hanall Biopharma pipeline, October 2018)